Theriva Biologics Files 8-K Report
Ticker: TOVX · Form: 8-K · Filed: May 16, 2024 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | May 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $1.22 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing
TL;DR
Theriva Biologics filed an 8-K, standard corporate update, no major news.
AI Summary
On May 13, 2024, Theriva Biologics, Inc. filed an 8-K report detailing other events. The company, formerly known as Synthetic Biologics, Inc., is incorporated in Nevada and headquartered in Rockville, Maryland. This filing does not contain specific financial transactions or material agreements.
Why It Matters
This 8-K filing serves as a notification of events for Theriva Biologics, Inc., providing transparency to investors about the company's ongoing regulatory compliance and corporate actions.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for 'Other Events' and does not disclose any new material risks or significant financial changes.
Key Players & Entities
- Theriva Biologics, Inc. (company) — Registrant
- Synthetic Biologics, Inc. (company) — Former company name
- May 13, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Rockville, Maryland (location) — Principal executive offices
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is May 13, 2024.
What was Theriva Biologics, Inc. formerly known as?
Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc.
In which state is Theriva Biologics, Inc. incorporated?
Theriva Biologics, Inc. is incorporated in Nevada.
What is the address of Theriva Biologics, Inc.'s principal executive offices?
The address of the principal executive offices is 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850.
What is the SEC Act under which this 8-K is filed?
This 8-K is filed under the Securities Exchange Act of 1934.
Filing Stats: 422 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-05-16 07:30:14
Key Financial Figures
- $0.001 — h registered Common stock, par value $0.001 per share TOVX NYSE American Indica
- $1.22 — s common stock at a conversion price of $1.22 per share. SIGNATURES Pursuant to th
Filing Documents
- tm2414630d1_8k.htm (8-K) — 23KB
- 0001104659-24-062270.txt ( ) — 192KB
- syn-20240513.xsd (EX-101.SCH) — 3KB
- syn-20240513_lab.xml (EX-101.LAB) — 33KB
- syn-20240513_pre.xml (EX-101.PRE) — 22KB
- tm2414630d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On May 13, 2024, Theriva Biologics, Inc. (the "Company") received a notice of conversion from the holder of 135,431 shares of its Series C Convertible Preferred Stock to convert the 135,431 shares of Series C Convertible Preferred Stock into 888,072 shares of the Company's common stock at a conversion price of $1.22 per share.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 16, 2024 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer